<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Perphenazine" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Perphenazine</book-part-id>
      <title-group>
        <title>Perphenazine</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Perindopril" document-type="chapter">Perindopril</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Pertuzumab" document-type="chapter">Pertuzumab</related-object>
    </book-part-meta>
    <body>
      <sec id="Perphenazine.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Perphenazine.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Perphenazine is a phenothiazine and antipsychotic agent, now rarely used in clinical practice. Perphenazine can cause mild and transient serum enzyme elevations and is a rare cause of clinically apparent acute and chronic cholestatic liver injury.</p>
        </sec>
        <sec id="Perphenazine.Background">
          <title>Background</title>
          <p>Perphenazine (per fen' a zeen) is a piperazine phenothiazine derivative which acts by postsynaptic inhibition of dopamine receptors. Perphenazine has other peripheral and central nervous system effects, producing both alpha adrenergic stimulation and blocking histamine- and serotonin-mediated effects. Perphenazine is indicated for the therapy of acute and psychosis and is also used for management of nausea and vomiting. Perphenazine was approved for use in the United States in 1957 and was formerly a commonly prescribed antipsychotic, but in recent years, has been replaced in large part by the atypical antipsychotics, which have fewer extrapyramidal side effects. Perphenazine is available in generic forms as tablets of 2, 4, 8 and 16 mg and previously under the brand name of Trilafon. Oral solutions are also available. Typical doses used to treat schizophrenia are 4 to 16 mg two to three times daily, attempting to reduce the dose as soon as possible to a minimum. Common side effects include drowsiness, dizziness, headache, blurred vision, dry mouth, constipation, tremor, restlessness, muscle spasms and weight gain. Uncommon but potentially severe adverse events include increased risk of death in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension and hypersensitivity reactions.</p>
        </sec>
        <sec id="Perphenazine.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Transient liver test abnormalities occur in a proportion of patients on long term therapy with perphenazine and other phenothiazines, but the elevations are usually mild, asymptomatic and reverse even with continuation of medication. Chlorpromazine, the prototype phenothiazine, is a well known cause clinically apparent acute liver injury which occurs in approximately 1% of treated patients. It is unclear whether perphenazine causes a similar syndrome, but if so, it is rare and far less common than with chlorpromazine. Case series of drug induced liver injury have occasionally listed perphenazine as a cause, but the clinical characteristics of the injury have not been described. Typical phenothiazine induced liver injury usually presents within 1 to 4 weeks of starting therapy, with a cholestatic or mixed pattern of serum enzyme elevations. Immunoallergic manifestations (fever and eosinophilia) are common but usually not prominent, and autoantibodies are rare. Phenothiazine induced jaundice can be severe and prolonged and result in vanishing bile duct syndrome, but is rarely fatal.</p>
          <p>Likelihood score: D (possible rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Perphenazine.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which perphenazine causes serum aminotransferase elevations is not known. The clinically apparent, cholestatic liver injury that occurs with many phenothiazines is likely to be due to hypersensitivity, being often accompanied by fever and eosinophilia and occurring with a shorted latency upon rechallenge. Perphenazine is extensively metabolized by the liver via sulfoxidation and oxidation, and some instances of serum aminotransferase elevations as well as more clinically apparent liver injury may be caused by production of a toxic intermediate of its metabolism.</p>
        </sec>
        <sec id="Perphenazine.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>The serum aminotransferase elevations that occur on perphenazine therapy are usually self-limited and do not require dose modification or discontinuation of therapy. The acute cholestatic hepatitis caused by phenothiazines is typically self-limited and benign, but should lead to prompt discontinuation. A proportion of cases are followed by prolonged jaundice and cholestasis, and many instances of vanishing bile duct syndrome have been attributed to chlorpromazine and prochlorperazine. Many patients with chronic cholestasis eventually improve, but they often have persistent enzyme elevations and biliary cirrhosis. Rechallenge usually causes a prompt recurrence of the liver injury and should be avoided. Patients with perphenazine induced liver injury may have cross sensitivity to other phenothiazines, but should tolerate the atypical antipsychotics without increased risk of liver injury.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntipsychoticAgents" document-type="chapter">Antipsychotic Agents</related-object></p>
          <p>Other Drugs in the Subclass, Phenothiazines: <related-object link-type="booklink" source-id="livertox" document-id="Chlorpromazine" document-type="chapter">Chlorpromazine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Fluphenazine" document-type="chapter">Fluphenazine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Prochlorperazine" document-type="chapter">Prochlorperazine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Thioridazine" document-type="chapter">Thioridazine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Trifluoperazine" document-type="chapter">Trifluoperazine</related-object></p>
        </sec>
      </sec>
      <sec id="Perphenazine.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Perphenazine &#x02013; Generic, Trilafon&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antipsychotic Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Perphenazine">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Perphenazine.CHEMICAL_FORMULA_AND_STRUCT">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Perphenazine.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Perphenazine.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Perphenazine.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Perphenazine.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Perphenazine.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Perphenazine.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Perphenazine</td>
                <td headers="hd_h_Perphenazine.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134971796">58-39-9</ext-link>
                </td>
                <td headers="hd_h_Perphenazine.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C21-H26-Cl-N3-O-S</td>
                <td headers="hd_h_Perphenazine.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134971796" document-id-type="sid" document-type="summary" object-id="134971796" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Perphenazine.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 01 July 2020</p>
        <ref-list id="Perphenazine.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Perphenazine.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Neuroleptic drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 483-91.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity of neuroleptic drugs including phenothiazines published in 1999; several hundred cases of chlorpromazine jaundice have been reported, usually cholestatic, arising after 1-5 weeks, often with fever and eosinophilia, sometimes causing vanishing bile duct syndrome; other phenothiazines have only rarely been linked to liver injury, except for prochlorperazine).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Perphenazine.REF.larry.2013">
            <mixed-citation publication-type="book">Larry D, Ripault MP. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 447-62.<annotation><p><italic toggle="yes">(Review of phenothiazine hepatotoxicity mentions that hundreds of cases of chlorpromazine jaundice have been published, frequency ~0.5-1%; onset in 2-5 weeks, usually acute cholestatic hepatitis with jaundice and pruritus; prodrome of fever and abdominal pain is common; prolonged course in 7%; similar injury can be seen with other phenothiazines but much less commonly).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Perphenazine.REF.meyer.2011">
            <mixed-citation publication-type="book">Meyer JM. Pharmacotherapy of psychosis and mania. In, Brunton LL, Chabner BA, Knollman BA, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 417-56.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Perphenazine.REF.cook.1965.175">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cook</surname>
                  <given-names>GC</given-names>
                </name>
                <name name-style="western">
                  <surname>Sherlock</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Jaundice and its relation to therapeutic agents.</article-title>
              <source>Lancet</source>
              <year>1965</year>
              <volume>1</volume>
              <fpage>175</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Summary of cases of drug induced liver disease seen at Royal Free Hospital from 1959-65; 11 cases of acute liver failure including 3 due to iproniazid, 2 phenelzine, 2 phenoxypropazine, 1 prochlorperazine and 3 halogenated anesthetics; 20 cases of cholestatic hepatitis including 18 due to chlorpromazine, 1 perphenazine and 1 nitrofurantoin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">14238042</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.mcqueen.1963.460">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>McQueen</surname>
                  <given-names>EG</given-names>
                </name>
              </person-group>
              <article-title>Toxic effects of phenothiazine tranquillizers.</article-title>
              <source>N Z Med J</source>
              <year>1963</year>
              <volume>62</volume>
              <fpage>460</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the phenothiazines and their side effects; &#x0201c;Jaundice has occurred in about 1% of patients taking chlorpromazine and also, although less frequently, in patients taking one of the more recently developed analogues&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">14073060</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.walker.1966.631">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Walker</surname>
                  <given-names>CO</given-names>
                </name>
                <name name-style="western">
                  <surname>Combes</surname>
                  <given-names>B</given-names>
                </name>
              </person-group>
              <article-title>Biliary cirrhosis induced by chlorpromazine.</article-title>
              <source>Gastroenterology</source>
              <year>1966</year>
              <volume>51</volume>
              <fpage>631</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(A 32 year old woman and a 31 year old man developed persistent jaundice [&#x0003e;4 years], cholestasis and liver fibrosis 3 and 4 weeks after starting chlorpromazine; acute cholestatic hepatitis evolving into chronic form, with biopsies showing cirrhosis and complications of portal hypertension).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5926937</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.ishak.1972.283">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ishak</surname>
                  <given-names>KG</given-names>
                </name>
                <name name-style="western">
                  <surname>Irey</surname>
                  <given-names>NS</given-names>
                </name>
              </person-group>
              <article-title>Hepatic injury associated with the phenothiazines. Clinicopathologic and follow-up study of 36 patients.</article-title>
              <source>Arch Pathol</source>
              <year>1972</year>
              <volume>93</volume>
              <fpage>283</fpage>
              <lpage>304</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of 36 liver biopsies of phenothiazine induced hepatotoxicity from the files of the Armed Forces Institute of Pathology; 33 due to chlorpromazine, 3 prochlorperazine; mean onset 15 days, eosinophilia in 73%, mean bilirubin 12.4 mg/dL, Alk P ~8 fold elevated, ALT 146 U/L; 6 [17%] had prolonged course for 10-16 months).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">5017281</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.d_ssing.1982.205">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>D&#x000f8;ssing</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Andreasen</surname>
                  <given-names>PB</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs.</article-title>
              <source>Scand J Gastroenterol</source>
              <year>1982</year>
              <volume>17</volume>
              <fpage>205</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 572 cases of drug induced liver disease seen between 1968-78 in Denmark, 54 were attributed to chlorpromazine [9%, ranking 2nd behind halothane], latency averaging 14 days [range 11-46]; 5 deaths; no other phenothiazine mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6982502</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.munyon.1987.182">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Munyon</surname>
                  <given-names>WH</given-names>
                </name>
                <name name-style="western">
                  <surname>Salo</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Briones</surname>
                  <given-names>DF</given-names>
                </name>
              </person-group>
              <article-title>Cytotoxic effects of neuroleptic drugs.</article-title>
              <source>Psychopharmacology (Berl)</source>
              <year>1987</year>
              <volume>91</volume>
              <fpage>182</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In vitro assay for cytotoxicity of 8 neuroleptic drugs found that chlorpromazine was more toxic than haloperidol and loxapine, but similar to other phenothiazines).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2883697</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.regal.1987.787">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Regal</surname>
                  <given-names>RE</given-names>
                </name>
                <name name-style="western">
                  <surname>Bili</surname>
                  <given-names>JE</given-names>
                </name>
                <name name-style="western">
                  <surname>Glazer</surname>
                  <given-names>HM</given-names>
                </name>
              </person-group>
              <article-title>Phenothiazine-induced cholestatic jaundice.</article-title>
              <source>Clinical Pharmacy</source>
              <year>1987</year>
              <volume>6</volume>
              <fpage>787</fpage>
              <lpage>94</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of phenothiazine induced liver injury; cross sensitivity is rare &#x0201c;but does exist&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2905941</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.pillans.1996.315">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pillans</surname>
                  <given-names>PI</given-names>
                </name>
              </person-group>
              <article-title>Drug associated hepatic reactions in New Zealand: 21 years experience.</article-title>
              <source>N Z Med J</source>
              <year>1996</year>
              <volume>109</volume>
              <fpage>315</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Over 21 year period in New Zealand, there were 943 official reports of liver injury involving 205 drugs; chlorpromazine was in the top 20 drugs implicated accounting for 2.7% of cases; prochlorperazine was cause of 4 cases, but other phenothiazines were not mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8816722</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.gaertner.2001.215">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gaertner</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Altendorf</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Batra</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Gaertner</surname>
                  <given-names>HJ</given-names>
                </name>
              </person-group>
              <article-title>Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses.</article-title>
              <source>J Clin Psychopharmacol</source>
              <year>2001</year>
              <volume>21</volume>
              <fpage>215</fpage>
              <lpage>22</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Retrospective review of 233 psychiatric inpatients between 1980-92; any increase in ALT in 78% of patients on clozapine, 50% haloperidol and 15% perphenazine; 3-fold increase in ALT in 15% with clozapine, 2.4% with haloperidol and 1.4% perphenazine; no elevation in alkaline phosphatase with perphenazine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">11270919</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.sabat_.2007.1401">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sabat&#x000e9;</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Ib&#x000e1;&#x000f1;ez</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>P&#x000e9;rez</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Vidal</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Buti</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Xiol</surname>
                  <given-names>X</given-names>
                </name>
                <name name-style="western">
                  <surname>Mas</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Risk of acute liver injury associated with the use of drugs: a multicentre population survey.</article-title>
              <source>Aliment Pharmacol Ther</source>
              <year>2007</year>
              <volume>25</volume>
              <fpage>1401</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 126 cases of drug induced liver injury seen in Spain between 1993-2000, 3 were due to chlorpromazine with relative risk of 613: frequency of 261 per 100,000 person year exposures; no other phenothiazine mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17539979</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.kane.2007.213">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kane</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Meltzer</surname>
                  <given-names>HY</given-names>
                </name>
                <name name-style="western">
                  <surname>Carson</surname>
                  <given-names>WH</given-names>
                  <suffix>Jr</suffix>
                </name>
                <name name-style="western">
                  <surname>McQuade</surname>
                  <given-names>RD</given-names>
                </name>
                <name name-style="western">
                  <surname>Marcus</surname>
                  <given-names>RN</given-names>
                </name>
                <name name-style="western">
                  <surname>Sanchez</surname>
                  <given-names>R</given-names>
                </name>
                <collab>Aripiprazole Study Group</collab>
              </person-group>
              <article-title>Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.</article-title>
              <source>J Clin Psychiatry</source>
              <year>2007</year>
              <volume>68</volume>
              <fpage>213</fpage>
              <lpage>23</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of aripiprazole vs perphenazine in 416 adults with treatment resistant schizophrenia; the "incidence of potentially clinically significant laboratory abnormalities during the study was low" and there was no mention of ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17335319</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were due to phenothiazines).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reuben</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Koch</surname>
                  <given-names>DG</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WM</given-names>
                </name>
                <collab>Acute Liver Failure Study Group</collab>
              </person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury including 4 due to psychotropic agents; one each for quetiapine, nefazodone, fluoxetine and venlafaxine, but none for phenothiazines).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.molleston.2011.182">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Molleston</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Lopez</surname>
                  <given-names>MJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Kleiner</surname>
                  <given-names>DE</given-names>
                </name>
                <name name-style="western">
                  <surname>Gu</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <collab>Drug-induced Liver Injury Network</collab>
              </person-group>
              <article-title>Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.</article-title>
              <source>J Pediatr Gastroenterol Nutr</source>
              <year>2011</year>
              <volume>53</volume>
              <fpage>182</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 30 children with suspected drug induced liver injury, half [n=15] were due to antimicrobials [minocycline 4, INH 3, azithromycin 3] and the rest largely due to CNS agents and anticonvulsants; one case was attributed to perphenazine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21788760</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF18">
            <element-citation publication-type="journal">
              <article-title>Drugs for psychiatric disorders.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2013</year>
              <volume>11</volume>
              <issue>130</issue>
              <fpage>53</fpage>
              <lpage>64</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review and recommendations on use of antidepressants and antipsychotic medications including perphenazine; no discussion of hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23715100</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.marwick.2012.244">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Marwick</surname>
                  <given-names>KF</given-names>
                </name>
                <name name-style="western">
                  <surname>Taylor</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Walker</surname>
                  <given-names>SW</given-names>
                </name>
              </person-group>
              <article-title>Antipsychotics and abnormal liver function tests: systematic review.</article-title>
              <source>Clin Neuropharmacol</source>
              <year>2012</year>
              <volume>35</volume>
              <fpage>244</fpage>
              <lpage>53</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of the literature found rates of any serum enzyme elevation during antipsychotic therapy to range from 5-78% and "clinically significant' elevations in 0-15%; does not list perphenazine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22986798</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, only one of which was attributed to chlorpromazine, the only antipsychotic medication listed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 5 cases [0.6%] were attributed to antipsychotic agents, including 3 due to quetiapine and 2 to olanzapine, but none to perphenazine or other phenothiazines]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF22">
            <element-citation publication-type="journal">
              <article-title>Drugs for psychotic disorders.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2016</year>
              <volume>58</volume>
              <issue>1510</issue>
              <fpage>160</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review of medications available in the US for therapy of psychotic disorders; mentions that the phenothiazines commonly cause sedation, postural hypotension and weight gain and often have extrapyramidal effects, but does not mention ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">27960194</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.schreiner.2017.339">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Schreiner</surname>
                  <given-names>NM</given-names>
                </name>
                <name name-style="western">
                  <surname>Windham</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Barker</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Atypical neuroleptic malignant syndrome: diagnosis and proposal for an expanded treatment algorithm: a case report.</article-title>
              <source>A A Case Rep</source>
              <year>2017</year>
              <volume>9</volume>
              <fpage>339</fpage>
              <lpage>43</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(48 year old man with bipolar disorder and NASH underwent liver transplantation and developed confusion, dyskinesia, rigidity, hyperthermia and tachycardia/tachypnea postoperatively having been given lithium, lamotrigine, promethazine and ziprasidone, responding to therapy of neuroleptic malignant syndrome with benzodiazepines and propofol).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28767476</pub-id>
            </element-citation>
          </ref>
          <ref id="Perphenazine.REF.baeza.2018.463">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Baeza</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>de la Serna</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Calvo-Escalona</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Merch&#x000e1;n-Naranjo</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Rodr&#x000ed;guez-Latorre</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Mart&#x000ed;nez-Cantarero</surname>
                  <given-names>MC</given-names>
                </name>
                <name name-style="western">
                  <surname>Andr&#x000e9;s</surname>
                  <given-names>P</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>One-year prospective study of liver function tests in children and adolescents on second-generation antipsychotics: is there a link with metabolic syndrome?</article-title>
              <source>J Child Adolesc Psychopharmacol</source>
              <year>2018</year>
              <volume>28</volume>
              <fpage>463</fpage>
              <lpage>73</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 216 children and adolescents starting atypical antipsychotics, mean weight gain at 6 months was 6.5 kg and mean ALT levels increased by 8.6 U/L, while among 37 taking olanzapine mean weight gain was 10.3 kg and ALT increase 2.6 U/L, increases in ALT associated with development of the metabolic syndrome, mean ALT increasing by 27.8 U/L at 6 months).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">29975563</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Perphenazine.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Perphenazine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Perphenazine: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Perphenazine">Trials on Perphenazine: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
